OncoMatch/Clinical Trials/NCT07080242
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Official title: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Is NCT07080242 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies BL-M14D1 for small cell lung cancer metastatic or locally advanced.
Treatment: BL-M14D1 — The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Prostate Cancer
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: DLL3 expression (positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — advanced/metastatic
failed at least 1 line of standard therapy in the advanced/metastatic setting or are unable to receive standard treatment
Must have received: platinum-based chemotherapy — advanced/metastatic SCLC
For SCLC, the participant must have failed at least 1 line of platinum therapy in the advanced/metastatic setting.
Cannot have received: topoisomerase inhibitor-based antibody-drug conjugate
No prior topoisomerase inhibitor-based ADC therapy is permitted.
Cannot have received: topoisomerase inhibitor-based antibody-drug conjugate
Participants who have received prior topoisomerase inhibitor-based ADC therapy
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
No serious cardiac dysfunction and left ventricular ejection fraction ≥50%
No serious cardiac dysfunction and left ventricular ejection fraction ≥50%. Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clearview Cancer Institute · Huntsville, Alabama
- Los Alamitos Hematology/Oncology Medical Group · Glendale, California
- MemorialCare Long Beach Medical Center · Long Beach, California
- Valkyrie Clinical Trials · Los Angeles, California
- UCLA · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07080242 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase inhibitor-based antibody-drug conjugate, topoisomerase inhibitor-based antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require DLL3?
Yes, DLL3 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify